Share Price | Reneo Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Reneo Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Reneo Pharmaceuticals, Inc. has a market capitalization of 30.62 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, Reneo Pharmaceuticals reported net sales of 0.00 million and a net profit of -60.17 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 103.83 million and total assets of 114.91 million.

Q: What does Reneo Pharmaceuticals, Inc. do?

Overview: Reneo Pharmaceuticals, Inc. operates within the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -16 Million (Quarterly Results - Mar 2025) Market Cap: USD 30.62 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.06 Return on Equity: -66.39% Price to Book: 0.34Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Reneo Pharmaceuticals, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Reneo Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The Bollinger Bands show a bullish weekly trend but a bearish monthly trend. Overall, the indicators reflect a mixed technical picture, leaning towards bearish in the short term.In terms of performance, Reneo Pharmaceuticals has significantly underperformed compared to the S&P 500, with a year-to-date return of -71.16% versus the S&P 500's 12.22%, and a one-year return of -83.47% compared to 17.14% for the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

48.16 k

Shareholding (Mar 2025)

FII

6.93%

Held by 28 FIIs

DII

60.39%

Held by 12 DIIs

Promoter

22.55%

How big is Reneo Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Reneo Pharmaceuticals, Inc. has a market capitalization of 30.62 million, with net sales of 0.00 million and a net profit of -60.17 million for the latest four quarters. As of December 2024, the company reported shareholder's funds of 103.83 million and total assets of 114.91 million.

View full answer

What does Reneo Pharmaceuticals, Inc. do?

22-Jun-2025

Reneo Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $16 million and a market cap of $30.62 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -66.39%.

View full answer

Is Reneo Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Reneo Pharmaceuticals shows a mildly bearish trend with mixed technical indicators and has significantly underperformed the S&P 500, with year-to-date and one-year returns of -71.16% and -83.47%, respectively.

View full answer

Compare Reneo Pharmaceuticals, Inc. with Similar Stocks

Xeris Biopharma Holdings, Inc.ProKidney Corp.Seres Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 35 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-89.82%

Price to Book

0.45

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-15 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-53.23%

6 Months

-83.1%

1 Year

-86.19%

2 Years

-97.4%

3 Years

-90.21%

4 Years

-97.83%

5 Years

0.0%

Reneo Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-255.72%

EBIT to Interest (avg)

-41.19

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.06

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.40

EV to EBIT

0.91

EV to EBITDA

0.92

EV to Capital Employed

10.92

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1196.18%

ROE (Latest)

-66.39%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 20 Schemes (10.13%)

Foreign Institutions

Held by 28 Foreign Institutions (6.93%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -185.19% vs 72.31% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.10",
          "val2": "-6.40",
          "chgp": "-151.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.40",
          "val2": "-5.40",
          "chgp": "-185.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -49.29% vs 32.12% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-53.50",
          "val2": "-36.40",
          "chgp": "-46.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-52.70",
          "val2": "-35.30",
          "chgp": "-49.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-16.10

-6.40

-151.56%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-15.40

-5.40

-185.19%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -185.19% vs 72.31% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-53.50

-36.40

-46.98%

Interest

0.10

0.00

Exceptional Items

0.10

0.00

Consolidate Net Profit

-52.70

-35.30

-49.29%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -49.29% vs 32.12% in Dec 2023

All Annual Results

Company CV

About Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Reneo Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Reneo Pharmaceuticals, Inc.?

Watch in Real-Time

What does Reneo Pharmaceuticals, Inc. do?

Is Reneo Pharmaceuticals, Inc. technically bullish or bearish?

Compare Reneo Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Reneo Pharmaceuticals, Inc.

Company Coordinates